Bimzelx (bimekizumab-bkzx) — Highmark
Hidradenitis Suppurativa (HS)
Initial criteria
- age ≥ 18 years
- diagnosis of moderate to severe HS
- prescribed by or in consultation with a dermatologist
- therapeutic failure or intolerance to at least one step 1 plan-preferred agent for HS
Reauthorization criteria
- disease stability or beneficial response to therapy